HDAC8 inhibitors can remodel the epigenetic program of tumor cells and effectively restore H3K27 acetylation, thereby promoting the infiltration of CD8+ T cells into tumor sites, which, in combination with anti‐PD‐1 therapy, induces an effective and long‐lasting anti‐tumor response.[30] Therefore, we explored the relationship between HDAC8 and H3K27ac in CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.